Table 1.

Leukocyte infiltration in response to mycoplasmas and mycoplasmal lipopeptide MALP-2 after 72 h

TreatmentNo. (in millions) or % ± SD of the indicated cells
PEC (n)Monocytes/macrophagesLymphocytesPMN
n%n%n%
M. fermentans (0.2 mg of protein)a 14.8 ± 5.97.1 ± 3b 48.7 ± 8.93.6 ± 225.4 ± 12b 3.9 ± 2.924.2 ± 14.8b
MALP-2 (9 μg)11.2 ± 3.1b 5 ± 1.2b 47.4 ± 15.23.5 ± 1.232 ± 11b 2.6 ± 2.720.2 ± 13.2b
Liposome-encapsulated MALP-2 (9 μg)8.5 ± 1.2c 4.9 ± 0.9c 57.6 ± 8.1c 2.9 ± 133.4 ± 9c 0.8 ± 0.2c 9.7 ± 2.2c
Control liposomes6.4 ± 1.92.9 ± 1.244.5 ± 6.83.2 ± 0.951.8 ± 6.70.2 ± 0.082.9 ± 1.4
NaCl (0.9%)5.8 ± 0.52.8 ± 0.447.9 ± 1.72.8 ± 0.248.8 ± 10.05 ± 0.030.9 ± 0.6
  • a Estimated to contain about 0.9 μg of MALP-2 according to MSA in the nitric oxide release assay.

  • b Significantly different (P < 0.05) from values for saline-treated animals as calculated by Student’s t test.

  • c Significantly different (P < 0.05) from values for animals injected with control liposomes as calculated by Student’s t test.